Trexquant Investment LP Edgewise Therapeutics, Inc. Transaction History

Trexquant Investment LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$9.25 - $19.97 $654,354 - $1.41 Million	70,741 Added 127.25%	126,332 $2.3 Million
Q4 2023 Feb 09, 2024	BUY	$5.51 - $12.1 $306,306 - $672,651	55,591 New	55,591 $608,000
Q4 2022 Feb 13, 2023	BUY	$7.58 - $11.08 $111,820 - $163,452	14,752 Added 85.46%	32,014 $286,000
Q3 2022 Nov 14, 2022	SELL	$8.08 - $13.58 $100,264 - $168,514	-12,409 Reduced 41.82%	17,262 $170,000
Q2 2022 Aug 11, 2022	BUY	$5.67 - $9.87 $42,292 - $73,620	7,459 Added 33.58%	29,671 $236,000
Q1 2022 May 13, 2022	BUY	$9.1 - $18.97 $74,519 - $155,345	8,189 Added 58.4%	22,212 $215,000
Q4 2021 Feb 14, 2022	BUY	$14.41 - $22.41 $202,071 - $314,255	14,023 New	14,023 $214,000

189

100M

2.17M

410K

Ticker EWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 63,171,700
Market Cap $1.76B
Description
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has c...

Get notified when there are updates to the investment portfolio of Trexquant Investment LP, based on Form 13F filings with the SEC.

Stay updated on Trexquant Investment LP with notifications on news.